Metagenomi Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit­ing toolbox, ther­a­peu­tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Metagenomi, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Metagenomi (MGX)

Shareholder Rights Advocates at Levi & Korsinsky Investigate Metagenomi, Inc. (MGX) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi, Inc. May Have Violated Securities Laws And Impacted Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry

NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Metagenomi, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MGX

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In Metagenomi, Inc. Can Join The Schall Law Firm's Inquiry Into Potential Securities Law Infractions

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Metagenomi Inc Committed Securities Fraud And Shareholders Are Urged To Reach Out

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Levi & Korsinsky Announces an Investigation on Behalf of Metagenomi, Inc. (MGX) Shareholders Who May Have Been Affected by Fraud

ATTENTION Metagenomi, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Impacted Investors To Help With An Inquiry

NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Lost Money on Metagenomi, Inc.(MGX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Metagenomi Inc For Securities Fraud And Individuals With Losses Are Urged To Join

Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study  in hemophilia A remains generally consistent with data previously released at 4.5 months

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc. May Have Violated Securities Regulations And The Schall Law Firm Seeks Investors' Participation In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Metagenomi Inc For Potential Securities Fraud And Stockholders Can Lend A Hand

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Metagenomi Inc. Are Invited To Partake In An Inquiry With The Schall Law Firm Into Whether Securities Laws Were Violated

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Looked Into For Securities Fraud And The Schall Law Firm Encourages Shareholder Participation

NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

Investors who Lost Money on Metagenomi, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MGX

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Can Join The Schall Law Firm In An Inquiry Into Whether Metagenomi Inc. Committed Securities Law Infractions

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci

Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc Is Being Looked Into For Securities Fraud And Shareholders Are Urged To Participate With The Schall Law Firm

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences:

Metagenomi to Participate in Upcoming Investor Conferences

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Metagenomi Inc. For Possible Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Metagenomi Inc. Is Being Looked Into For Securities Fraud And The Schall Law Firm Wants Shareholders To Offer Assistance

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws. On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration.

News for Metagenomi Inc Stock (MGX)